The ‘Istituto Lusofarmaco d'Italia’ was established in Milan in 1951 by two Portuguese businessmen. As an offshoot of the homonymous ‘Instituto Luso-Fármaco de Lisboa,’ it was created to manufacture and market in Italy a series of pharmaceutical products that were already marketed in Portugal.
For many years, Lusofarmaco has been mainly a national company, with a portfolio focused on well-established medicinal products, which have been the reference drugs in their respective therapeutic areas.
Learn More +
Lusofarmaco can claim extensive know-how in various therapeutic areas: cardiovascular and respiratory diseases, antibiotic therapy and neuropsychiatry.
The Italian population has a prevalence of chronic pain of 21,7%, which corrresponds to approximately 13 millions inhabitants. It is therefore a problem of relevant importance, with a significant impact on the person. Neuropathic pain is associated with others conditions as anxiety, depression, sleep disturbances and reduced quality of life.